BridgeMD
Does human skeletal muscle possess an epigenetic memory of testosterone
EU CTIS ID: 2023-507815-37-00
What this study is testing
To compare the ability to retrain and enhance muscle size after a period of detraining / testosterone abstinence between earlier short-term testosterone groups and placebo controls.
- Therapeutic exploratory (Phase II)
A plain-language read of the study's public EU CTIS listing. The study team confirms the details.
Who can take part
You may be able to join if
- Sedentary males
- 55-70 years old
- Serum testosterone levels >8 nmol/L measured in the morning.
- Without any known illness, disease or other conditions.
- Undergone screening through medical questionnaire, physical examination, routine blood tests and urine samples
- Written informed consent received.
You likely can't join if
- Current or previous participation in a formal exercise regime.
- A BMI < 18 or > 30 kg·m2.
- Active cardiovascular disease: uncontrolled hypertension (BP > 160/100 mmHg), angina, heart failure (class III/IV), arrhythmia, right to left cardiac shunt, recent cardiac event
- Family history of early (<55y) death from cardiovascular disease.
- Haematocrit >50%
- Malignancy.
See the full eligibility criteria
- Sedentary males
- 55-70 years old
- Serum testosterone levels >8 nmol/L measured in the morning.
- Without any known illness, disease or other conditions.
- Undergone screening through medical questionnaire, physical examination, routine blood tests and urine samples
- Written informed consent received.
- Current or previous participation in a formal exercise regime.
- A BMI < 18 or > 30 kg·m2.
- Active cardiovascular disease: uncontrolled hypertension (BP > 160/100 mmHg), angina, heart failure (class III/IV), arrhythmia, right to left cardiac shunt, recent cardiac event
- Family history of early (<55y) death from cardiovascular disease.
- Haematocrit >50%
- Malignancy.
- Prostate-specific antigen (PSA) >4 ng/mL.
- Lower urinary tract symptoms
- Taking beta-adrenergic blocking agents, statins, non-steroidal anti-inflammatory drugs.
- Receiving oral anticoagulants
- Serum testosterone levels above the reference range for 50 year olds (>32 nmol/L) (Bjerner et al., 2009) measured in the morning
- Cerebrovascular disease: previous stroke, aneurysm (large vessel or intracranial), epilepsy.
- Respiratory diseases including: pulmonary hypertension, COPD, asthma, sleep apnoea.
- Metabolic disease: hyper and hypo parathyroidism, untreated hyper and hypothyroidism, Cushing's disease, type 1 or 2 diabetes.
- Active inflammatory bowel or renal disease.
- Current or previous steroid treatment or hormone replacement therapy.
- Clotting dysfunction.
- Musculoskeletal or neurological disorders.
- Alcohol or drug abuse.
The study team makes the final eligibility decision.
Questions & answers
Do participants get paid in this trial?
This listing doesn't specify compensation. Many trials still reimburse travel or offer a stipend, so it's worth asking the study team when you connect.
Is it free to join, and do I need insurance?
Searching and applying through BridgeMD is free. In clinical trials the study-related treatment and visits are generally provided at no cost to you. You usually don't need insurance to take part - confirm specifics with the study team.
How long does this study last?
The listing doesn't state an exact length. The study team walks you through the schedule and number of visits before you decide to enroll.
Who can join this trial?
This study is enrolling male, 65+ years, 18-64 years. The study team makes the final eligibility decision.
Explore other conditions
BridgeMD is an information and trial-matching tool - not medical advice, and not the study sponsor. Details come from EU CTIS; the study team decides eligibility.